Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > What if TH-1902 doesn't work?

<< Previous

Bullboard Posts

Next >>

Post by PWIB123on Oct 13, 2022 3:02pm

220 Views

Post# 35023091

What if TH-1902 doesn't work?

For those of you who have followed biotech stocks in the past, if TH-1902 ends up being a dud, what is the liklihood we wake up one day to a press release saying they're scrapping the program entirely? The fact they say things like we aren't ready to report recruitment numbers and hold out on posting details of things they are seeing keeps us in the dark.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China